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ABSTRACT Platelet aggregation, which occurs within seconds of activation, is generally considered to be mediated by fibrinogen
binding to glycoprotein Ilb-lila which becomes expressed as a fibrinogen receptor (FbR) on the activated platelet surface. This
receptor expression has, however, only been measured to date at relatively long activation times (> 15 min). We have therefore
developed a theoretical and experimental approach for determining FbR expression within seconds of platelet activation using flow
cytometry. The fluorescently labeled IgM monoclonal antibody FITC-PAC1, was used to report on the GPIlb-llia receptor for Fb
(FbR). Human citrated platelet-rich plasma (PRP; diluted 1:10) was incubated with adenosine diphosphate (ADP) or phorbol
myristate acetate (PMA) for varying times (T = 0-10 s, out to 60 min), followed by incubation with fluorescein isothiocyanate
(FITC)-PAC1 antibody at saturating concentrations. The time course of FITC-PAC1 binding was then measured for these variously
preactivated samples (different T) from the mean platelet-bound fluorescence (Fl), determined for .5 s of PAC1 addition by
dilution quenching and determination of fluorescence intensity histograms with the FACSTAR or FACSCAN (Becton-Dickinson
Canada, Mississauga, Ontario) flow cytometers. Both rapid, initial rate of increase in Fl (v) (related to PAC1 on-rates) and maximal
extent of increase (Flmj) were thus determined for different T values. These measurements yield the rate of formation of FbR (kl),
and both the rate (k2) and efficiency (a) of binding of PAC1 to FbR as a function of activator type and time of action. We have found
that ADP appears to cause rapid, maximal expression of FbR within 1-3 s (k, > 20 min-'), whereas PMA expresses FbR in a slow,
biphasic manner (k, - 0.01 and 0.2 min-'). However, k2 and a for maximal PMA activation are about two and three times greater,
respectively, than for maximal ADP-activation. Moreover, k2 decreases with post ADP activation time. These differences are
discussed in terms of altered FbR organization and accessibility. This kinetic approach can be widely used to analyze the dynamics
and organization of molecules on cell surfaces by flow cytometry, including studies of size-dependent subpopulations (see Part 11,
Frojmovic, M., and T. Wong. 1991. Biophys. J. 59:828-837).
INTRODUCTION
Platelet aggregation is generally mediated by fibrinogen
(Fb)1 (1-4) which can specifically bind to the platelet
membrane GPIIb-IIIa complex (1-7). However, this
complex must be transformed into a receptor for Fb
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'Abbreviations listed in this paper: ADP: adenosine diphosphate; F:P:
fluorescein:protein ratio in molar; FA: formaldehyde; Fb, FbR:
fibrinogen and receptor for Fb; FITC-PAC1: fluorescein isothiocy-
anate (FITC)-PAC1 antibody; Fl, Fl,.: mean fluorescence for a
platelet population and maximal Fl at equilibrium binding, respec-
tively; Fn: fibronectin; FSC: forward scatter; GA: glutaraldehyde; L:
large platelets (- top 20%); PMA: phorbol myristate acetate; PRP:
platelet rich plasma RGDS: arginine-glycine-aspartate-serine; R. T.:
room temperature; S: small platelets (- bottom 20%); SSC: side
scatter; t: total platelet activation time and/or incubation time of FITC
antibody with platelets; T: activation time of platelets preceding
addition of FITC-antibody; vT: initial rate of increase in Fl for a
preactivation time T, related to initial on-rate; VWF: von Willebrand
factor.
(FbR) via platelet activation which alters the GPIIb-IIIa
conformation and/or its microenvironment in the mem-
brane (3-5, 8). In this regard, the monoclonal antibody
PAC1 is an IgM antibody that binds only to this
activated form of the GPIIb-IIIa complex (5, 6). This
antibody probe has been shown to recognize an epitope
on the IIb-IIIa complex which is critical for Fb binding
and to contain an arginine-glycine-aspartate-serine
(RGDS) binding site (9) characteristic of adhesive
molecules (Fb, fibronectin [Fn] and von Willebrand
factor VIII [VWF]) (4, 7) which can all bind to the
transformed GPIIb-IIIa, typical of members of the inte-
grin family (3, 7). In plasma, it appears that Fb is the
most effective adhesive molecule for binding to the
transformed GPIIb-IIIa, which can then mediate aggrega-
tion (1, 4).
Unactivated platelets each contain - 50,000 copies of
GPIIb-IIIa which are uniformly distributed over the
platelet surface. Platelet activation causes shape change,
expression of newly transformed GPIIb-IIIa which can
then bind Fb, and ensuing aggregation (shown schemat-
ically in Fig. 1). Newly expressed GPIIb-IIIa (FbR) on
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FIGURE 1 Schematic for platelet activation and expression of fibrinogen receptors. The resting platelet is a smooth discocyte (A) containing
-50,000 copies of glycoprotein 'lb-,,,a in the surface membrane (inset). Activation causes shape change (B) and "transformation" of these
glycoproteins into FbR, (0) which can bind fibrinogen and allow platelet doublet and multiplet formation (C) occurring by 1 s after ADP addition
(14, 15). The arrangement of FbR and selection of platelet contacts is only hypothetical.
the surface of activated platelets have been reported to
vary from 10,000 to 80,000 receptors, with low esti-
mates for weak activators like adenosine diphosphate
(ADP) and highest ones for strong activators like throm-
bin or phorbol myristate acetate (PMA) (4, 10). It
appears that activators such as PMA, but not ADP, can
recruit a new pool of GPIIb-IIIa receptors from a-gran-
ules (4, 11). Finally, events after Fb binding are needed
to allow its functional expression in eliciting platelet-
platelet aggregation, likely related to (a) the increased
association of GPIIb-IIIa with cytoskeleton (1, 4); (b)
further conformational changes occurring in GPIIb-IIIa
after binding of the Fb (7, 12), and (c) clustering of the
GPIIb-IIIa receptors into patches after Fb binding
(2, 4, 13).
Although enormous progress has been made in the
biochemistry of platelet activation and of the platelet
membrane GPIIb-Il1, very little is known of the dynam-
ics of expression of the FbR and of its relation to the
dynamics of platelet aggregation. Platelets activated
with ADP immediately begin to change shape ( << 1 s),
and after a delay of 1 s, single platelets are maximally
recruited into microaggregates by 8-10 s with a half-time
of 3 s (14, 15). This is summarized schematically in
Fig. 1. We therefore wished to determine the dynamics
of expression of the transformed GPIIb-IIIa receptor for
Fb on such shape-changed platelets (Fig. 1) between 0
and 10 s of ADP activation, and to determine any
changes occurring in "steric accessibility" of this FbR
with increasing activation time. We hypothesized that
we might find a continuous expression of FbR between 1
and 10 s at the rate of > 1,000 new sites expressed per
second (4, 10).
The probe chosen for these kinetic studies was PAC.
Such rapid measurements could not be made with
traditional radiolabeled probes (1, 4, 10). We therefore
chose to use fluorescently labeled PAC1 and flow
cytometry (6), with PAC1 suited for studies in platelet-
rich plasma (PRP) as it readily displaces reversibly
bound Fb (6). We developed a rapid dilution quenching
protocol and appropriate theoretical treatments to as-
sess the rapid expression and dynamic changes in FbR.
This approach has yielded a novel general technique for
assessing the rapid dynamics of any cell surface molecule
as well as unexpected new insights into the kinetic
expression and nature of FbR formed on platelet sur-
faces activated with ADP and PMA.
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MATERIALS AND METHODS
Processing of PRP for activation and
flow cytometric measurements
Venous blood was obtained from healthy human donors who were not
on any medication. Whole blood (9 vol) was anticoagulated with 3.8%
sodium citrate (1 vol) and was centrifuged at 150g for 15 min at room
temperature to obtain PRP. The PRP was then incubated at 37°C for
30 min and an aliquot was tested for aggregation in response to
activator addition (typically, 0.2 PM PMA and 10-100 P,M ADP by
turbidimetry [15]). The PRP was diluted 10-fold by the addition of
prewarmed (37°C) Walsh-albumin buffer (modified Tyrodes buffer
(NaCl 140 mM, KCI 2.7 mM, NaHCO3 0.4 mM; pH 7.4) containing
0.1% glucose, 0.2 mM MgCl2, and 0.1% bovine serum albumin) to
obtain PRP 1:10 as described by Shattil et al. (6). It was further
incubated at room temperature (R.T.) for 15 min.
Unless otherwise stated, each sample for flow cytometric measure-
ment consisted of 22.5 PIu ofPRP 1:10, plus 2.5 PIl of activator (100 p.M
ADP or 0.2 p.M PMA) added at R.T. to 12 x 75 mm polystyrene tubes
for varying incubation times ('r) before the addition of fluoroscein
isothiocyanate (FITC)-antibody (4.5-5.5 pl). These activator concen-
trations were chosen to ensure maximal responses in all PRP samples.
Mixing was routinely done by rapid hand-swirling, for < 1 s, to ensure
complete mixing of reagents but negligible aggregation during the 1 s
latent time reported for samples stirred in a cuvette; the extent of
platelet aggregation was determined by microscopy (14).
Optimal times X of activation yielding maximal rates ofPAC binding
site expression were found to be o 10 s and > 25 min for ADP and
PMA, respectively. For -T > 25 min for PMA, > 100 PI of PRP (1:10)
was preactivated with PMA, and 25 p.l aliquots were then used for
FITC-PAC1 binding studies, with no differences observed for T varying
between 25 and 60 min. Incubation time (t) of the PRP (1:10) (+
activator) with FITC-antibody was varied from 5 s to 60 min before the
addition of Walsh buffer (10 vol) to quench-dilute the reaction
mixture. A few samples were prepared for live measurements in the
flow cytometer (no dilution), using > 4 vol of PRP (1:10) (90 P,) and
the same final concentrations of activator and antibody (116 PI final
vol). The final concentration of FITC-antibody in PRP (1:10) was
chosen so as to give saturation conditions ensuring > 90% of maximal
fluorescence values after >30 min binding to maximally activated
platelets as previously described (6); this was -25 and 40 pg/ml
(±+10%) for the two different preparations used (fluorescein:protein
[F:P] ratios were respectively 7.7 and 7.0).
Fixation experiments
In preliminary experiments, our primary strategy was to fix platelets
with aldehyde in order to trap and arrest the formation of new
FITC-PAC1 binding sites at very early activation times with ADP
( < 10 s) without causing destruction of these new sites as reported for
1% formaldehyde fixation (6). We found that addition of as little as
0.15% formaldehyde (FA) or 0.10% FA plus 0.05% glutaraldehyde
(GA) (4 vol) to control PRP (undiluted) at 37°C for 30 min could (a)
prevent any activation associated with platelet shape change, and (b)
did not yield enhancement in autofluorescence seen with > 0.5% GA
fixation. However, such fixation of PRP preactivated with 100 p.M
ADP or 0.2 p.M PMA (T = 15 and 25 min, respectively) caused 70%
reduction (50-80% for six donors evaluated) in maximal Fl at
equilibrium binding (Fl,,,,) compared to nonfixed samples; fixed
platelets were diluted 1:10 as above for flow cytometry. Moreover,
fixation alone caused >5% of Fl.. to be expressed when excess
fixative was neutralized with <0.1 M glycine (final concentration)
added 3 s after fixative addition, a modification of a procedure
reported by George et al. (16). This is an underestimate of "activation"
given major "disappearance" of Fl. above. Pelleting and washing of
platelets after fixation, or use of glycine, or studies with washed
platelets freed of plasma proteins by pelleting and resuspension (16)
did not alter the spontaneous activation and major destruction of
FITC-PAC1 binding sites.
Flow cytometry measurements
The platelet samples were analyzed for 2,500-5,000 cells in a
FASCSTAR or FACSCAN flow cytometer (Becton-Dickinson Can-
ada, Mississauga, Ontario). Light scatter and fluorescence data (for-
ward scatter [FSC], side scatter [SSC], and one color fluorescence
[F11]) were obtained with flow cytometer gain settings in the logarith-
mic mode and analyzed with Becton-Dickinson Canada C30 software
on a model 300 computer (Hewlett-Packard Co, Palo Alto, CA) to
yield dual parameter dot plots, single parameter histograms, or mean
values. Comparable results were obtained with the two flow cytome-
ters, with values -50% greater with the FACSTAR than with the
FACSCAN (Becton-Dickinson Canada). Platelets were distinguished
from background/cellular debris and electronic noise on the basis of
forward and side scatter dot plots by setting a lower FSC threshold to
exclude the background during data acquisition, as previously reported
(6). These dual parameter dot plots, shown as contour plots (contour
level set at a minimum of five points) (Fig. 2A) were distinct for
control PRP or PRP maximally preactivated with ADP or PMA, but
rectangular gates were set to enclose the complete contour plots
(Fig. 2A) (this included >95% of all particles acquired above the
lower threshold). The fluorescence histograms for these gated popula-
tions were then obtained (Fig. 2B); gates were set to include the
entire histogram, typically between 1.1 and 5,000 fluorescence units for
all samples (Fig. 2 B); mean and mode fluorescence values were
determined with the Becton-Dickenson Canada C30 software which
obtains the linear channel numbers, determines the average values,
and then converts to mean log channel number (for a fixed 64 channels
per decade). For both unactivated and maximally activated platelets,
after > 30 min of FITC-PAC1 binding to the platelets, the mean and
mode values for fluorescence (F) and FSC for a platelet population
were within <5% of each other due to the symmetrical shapes of the
histograms. Mean values of Fl are reported. Unless otherwise shown,
Fl values associated with FITC-PAC1 binding to activated platelets
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FIGURE 2 Detection of platelets and measurement of fluorescence
histograms for FITC-PAC1 binding to platelets. The dot plots of SSC
and FSC (A) and the fluorescence histograms of the gated platelets
(B) are shown for control PRP (-), and for PRP preactivated with
100 ,uMADP for 15 min (r = 15 min) (- - -) or with 0.2 ,uMPMA for 25
min ( = 25min)(--- -). The samples were incubated with FITC-PAC1
for 30 min (t = 30 min) representing the time for maximal binding, and
quench diluted just before analysis (see Methods). Mean FSC was
77, 92, and 102, respectively, for control, ADP- and PMA-treated
platelets.
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have been corrected for background binding by subtraction of Fl
values for FITC-PAC1 binding in the absence of activator.
For dilution-quenched samples, flow cytometry data were routinely
collected within 30-60 s of dilution quenching to minimize any
postdilution time-dependent changes. Fl,..n values so measured for
PRP maximally preactivated with PMA (r = 25 min) and incubated
with FITC-PAC1 for > 30 min before dilution, did not significantly
change between 30 s and 5 min. Live measurements with PRP (1:10)
containing FITC-PAC1 (with no further dilution) were made over a 10
s interval, with the mean value (t) used for Fl versus t plots (e.g.,
t = 10-20 s for data collection, t = 15 s) (Fig. 3A). No significant
differences were observed in Fl versus t for quench-diluted (observed
< 60 s postdilution) versus live experiments conducted in parallel for
early binding times of FITC-PAC1 to maximally preactivated platelets
(Fig. 3 A). Similarly, no significant off-rate was observed for preacti-
vated samples dilution quenched after 5, 15, or 30 s incubation with
FITC-PAC1 when followed in real time between 15 and 120 s
postdilution. The < 15% apparent increase in Fl which could occur
due to significant on-rates over the 0 s postdilution (Fig. 3 B) is,
however, within the reproducibility of any one measurement. Thus,
triplicate measurements of Fl at various time points shown in Fig. 3A
made for six donors gave standard deviations in mean values of t 15%
(range 2-33%) for both live and quench-diluted samples.
to test the nonspecific binding of IgM to platelets (see Fig. 5) were
generously provided by Dr. J. Rauch (Montreal General Hospital,
Montreal, Canada): the B110 and Bill which did not bind to
phospholipids, and 9604 which did (17); FITC labeling procedure and
F:P ratios were as for the PAC1.
Materials and chemicals
All chemicals and reagents, unless otherwise specified, were pur-
chased from Sigma Chemical Co. (St. Louis, MO). Platelet activators
ADP and PMA were diluted in Walsh buffer from respective stocks of
0.02 M (in Tyrode's pH 7.4) and 1.6 mM (in 100% ethanol) stored at
-20°C. Vehicle additions of activator to 10-fold diluted platelet-rich
plasma were < 10% (vol/vol). Fluorescein isothiocyanate (FITC;
Isomer I, on celite 10%) used for monoclonal antibody labeling was
purchased from Behring Diagnostics (La Jolla, CA). Aldehyde solu-
tions used for platelet fixation were freshly prepared as previously
described from solid paraformaldehyde (Fisher Scientific, Montreal,
Canada) and 8% glutaraldehyde solution in sealed ampoules (Poly-
sciences Inc., Warrington, PA).
Monoclonal antibodies
PACI, a murine monoclonal antibody having specificity for activated
glycoprotein IIb-IIIa (6), was generously provided by Dr. Sanford
Shattil (University of Pennsylvania, PA) (5, 6). FITC conjugation of
PAC1 was done as previously described (6); aliquoted stocks of this
material were stored at -70°C, freshly thawed on the day of use, and
spun for 5 min at 8,700g to remove antibody aggregates. The F:P molar
ratio was 7.7 and 7.0 for two different preparations for the FITC-
PACI. Human hybridoma IgM (lupus anticoagulant) antibodies used
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FIGURE 3 Effect of dilution quenching on the measured binding of
FITC-PAC1 to activated platelets. The time course of Fl associated
with platelets preactivated with 0.2 IFM PMA (T = 25 min) is com-
pared for (A) live samples measured in real time with no dilution
versus dilution-quenched samples measured between 30 and 60 s
postdilution for FITC-PAC1 binding times (t) of 15-60 s, and (B)
dilution-quenched samples as a function of time postdilution, for
FITC-PAC1 binding times of 5, 15, and 30 s preceding dilution
quenching. In (A), 1 and 4 vol of PRP (1:10) + FITC-PAC1 were used
for dilution quenched and live samples, respectively, with t reported as
the mean of the time needed to collect in real time (see Methods). The
Fl values were normalized to Fl,., obtained at t = 30 min; data are for
three experiments, with bars = ± 1 SD. In (B) data are for one donor;
regression lines are best-linear fits having correlation coefficients of
0.88, 0.85, and 0.92, respectively for t = 5, 15, and 30 s (p < 0.1 for
three lines). The line has been back-extrapolated to zero time
intercepts.
THEORY
Consider unactivated platelets (P) converted to acti-
vated platelets (P*) after addition of an activator:
p ,r---. (la)
New sites will be expressed for fibrinogen binding per
unit area of membrane surface (n) at a rate k,:
dn
= k, (nma- n) - k,n.b
Here, nmaxis the maximum number of sites which can be
activated, i.e., the maximum number of receptors ex-
pressed (FbR or PACl-binding sites formed); k-l is the
rate at which sites are deactivated, and T is the time of
activation.
The solution of Eq. 1 when k1 and k-l are constant is
k=* ma (2a)
wherek* = k1 + k-1. For short times (T -k 0)
d(nfnl.m ) (2b)
and hence,
n = nmaxklT. (2c)
Addition of a fluorescently labeled monoclonal anti-
body at an initial concentration mi (number of mole-
cules per unit volume) will yield binding of the marker
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molecules to activated sites at a rate k2:
din
dt = k2m. (1 - APmI/m.) (n - mi). (3)
Here mi is the number of marker molecules per unit area
which are bound to the activated sites; mo (1-Ap
Mi Inm) = m is the number of marker molecules per unit
volume in solution at time t, Ap being the total platelet
area per unit volume, and (n - mi) is the number of
unoccupied activated sites per unit area.
Now consider the following three conditions: (a)
when activator and marker molecules (PAC1) are added
together, so that at t = 0, n = 0, the solution of Eq. 3 for
short times (t -+ 0) is:
Ms= A2k,k2mnktlmMt
A. Experimental procedure for
determining k,
It follows from Eq. 7 that v, will increase in direct
proportion to the number of new sites, nS, present at the
time X of addition of FITC-PAC1. Considering maximal
activation associated with vm,., and nmu. we have
V,Vmax = n)nmax (8)
for constant k2, and using Eq. 2, we obtain for short times
d(v)v.m,) ki.
dT = (9a)
At longer T times (rewriting Eq. lb with k-l = 0),
d(vIvm,X)
= k1 (1 - vl/vmx). (9b)(4)
Eq. 4, together with the fact that m, n-
,x
as t x,
predicts that a plot of ms versus time t will be S-shaped.
(b) When excess marker molecules are used (mi * n.),
which are added after preactivation of the platelets for a
time , Eq. 3 reduces for short times to
Ms = k2m,n,t, (5)
where nr is the number of activated sites at time t = 0
(before marker molecule addition). With no preactiva-
tion, nr = 0 and Eq. 4 applies. Eq. 5 shows that when the
sites are preactivated, the number of marker molecules
binding to the activated sites is initially a linear function
of time, as well as a function of nT.
Now, consider a fluorescently labeled probe such as
FITC-PAC1 which binds specifically to new receptor
sites where the mean fluorescence of bound molecules
(Fl) is a linear function of the actual number of bound
molecules (mi) (6), i.e.,
Ms = c 'Fl, (6)
where c' = a constant relating Fl to actual numbers of
molecules, determined by the instrument and settings
chosen, and by the degree of labeling of the FITC-PAC1
(the F:P ratio [6]). It follows that the rate of increase in
Fl due to binding of FITC-PAC1 added at time T after
platelet activation is
dFl 1 dmi
VSr = dt =C dT (7a)
Combining Eqs. 5 and 7, we obtain for short times
VT = (k2mnjc') n,. (7b)
Thus, a plot of vlvm,, against T will yield the rate of
expression of new PACl-binding sites or FbR sites (kI)
at early and later times of activation.
B. Experimental procedure for
determining k2 m,
In the case where r is chosen so that maximal expression
of new receptors has occurred before addition of marker
molecule, Eq. 8 becomes
Vma = Ct °max = (k29l) Flm.,(
where k2 is the rate constant for the binding of marker
molecules to already expressed receptors, unchanging in
time, and nmax = Mm. (i.e., PAC1 has a 1:1 stoichiometry
with FbR at early times). Eq. 10 applies only when k-, =
0, i.e., no deactivation of PAC1 binding sites occurs.
Otherwise, nnm in Eq. 10 must be replaced by (k,/k *)n...
It follows from Eq. 10 that k9no is directly obtained from
Vm/Fl., for maximally preactivated platelets.
(c) Finally, we must consider that rate constants (k)
may change dynamically in time or be distinct for
different activators due to (1) a change in the source or
properties of the receptor (k, or k2 affected), (2) dynamic
"disappearance" of the receptor with time (k, compo-
nent), and (3) time-dependent steric changes in accessi-
bility of the receptor sites by the marker molecule m
(FITC-PAC1) (k2). In this case, Eq. 3 must be solved in
conjunction with Eq. lb in which k,, k , and k2 are time
dependent. However, for condition 2 above,
(v,)to = k2(T) m. n, (11)
where k2(T) is the value of k2 at time t -O 0 for varying
preactivation times T. k2(T) may vary due to activation-
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dependent changes in receptor's microenvironment or
surface organization (e.g., clustering).
Efficiency of PACI binding
From the conservation of marker molecules (i.e., the
number of marker molecules disappearing from solution
equals the number of molecules adsorbing onto plate-
lets), it can be shown that the efficiency a with which
marker molecules colliding with platelets are captured
by them, is given by
k2
=k S. (12)
Here a is the number of collisions between marker
molecules and platelets leading to capture (adsorption),
divided by the total number of such collisions; S is the
number of binding sites per platelet, and ksm is the rate
constant for the disappearance of marker molecules
from solution, as calculated from classical Smoluchowski
kinetics (18), assuming platelets and marker molecules
can be modeled as effective spheres of radius ap, and am
respectively. When ap, >> am,
ksm = 2DDm = (13)
tam 3'q a.'
Here Dm is the diffusion constant of a marker molecule,
k is Boltzman's constant, T the absolute temperature,
and q the viscosity of the medium. At room tempera-
ture, T = 398°K; in water, -r = 1 mPas, and taking ap, 1
pum (18) and am 30 nm (20), yields ksm -5.10-" m3s' .
From Eq. 12 it can be seen that from a measurement
of k2 and a knowledge of the number of sites, the
efficiency a can be determined. Relative a values are
obtained, for a given platelet preparation but for two
different activators, by
a11a2 = Vm.I/Vm.x2 (14)
obtained by combining Eqs. 10 and 12 and having nma =
S.
RESULTS
Methods of "trapping" FITC-PAC1
bound to platelets
Previous investigators have studied the binding of FITC-
PAC1 to platelets maximally activated with ADP or
PMA by incubating platelets with both activator and
antibody, and obtaining Fl values near equilibrium
conditions for maximal binding ( > 15 min) (5, 6). We
wanted to obtain Fl values as a function of the duration
of platelet preactivation (X), as well as for very early
times of incubation (t < 5 s) of platelets with the
FITC-PAC1 marker. Our theoretical model above pre-
dicted that such an approach would yield new informa-
tion on both the rate and extent of appearance of new
PAC1 binding sites which represents the expression of
new FbR. This approach therefore required rapid data
acquisition from PRP for times t < 5 s, given that
platelet aggregation, believed to require FbR, occurs
within 1 s of activation with > 2 ,M ADP, with 50% of
single platelets recruited by 3 s (Fig. 1) (14, 15).
Our first strategy was to quench FbR expression by
fixing platelets with aldehyde within 1-10 s of reaction
with 100 ,MADP and then incubating with FITC-PAC1
for varying times t. However, this approach had to be
abandoned as the FITC-PAC1 binding site (trans-
formed GPIIb-IIIa) appeared to become largely dena-
tured for the wide spectrum of fixation and "clean-up"
conditions explored as previously reported by Shattil et
al. for 1% formaldehyde fixation (6) (see Methods).
Fortunately, it was found that a simple 10-fold dilution
quenching of the PRP reaction mixture, and analysis
with the flow cytometer, within 60 s of dilution allowed a
measure of the fluorescence histogram and Fl values
corresponding to the precise time t at which the PRP +
activator + FITC-PAC1 was dilution quenched. This
approach allowed significant Fl values to be measured as
early as 5 s after addition of FITC-PAC1 to PRP (1:10)
samples (see Methods and Fig. 3). For PAC1 incubation
times t > 15-30 s, live experiments without dilution
quenching were equivalent to dilution-quenched experi-
ments (Methods and Fig. 3A), but the former requires
at least four times more PRP and antibody for any one
experiment. We therefore have chosen the dilution-
quench approach as the most efficient technique.
Extent of platelet aggregation during
activation and incubation
Given that aggregates of platelets will yield artifactually
high values of mean fluorescence per platelet, we made
direct measurements of the extent of aggregation in
representative samples fixed for flow cytometry using
microscopy as previously reported (14). Control PRP
1:10 examined out to 25 min of incubation at room
temperature without activator typically contained <2%
of all particles as doublets, and < 1% as triplets, with no
higher order aggregates. This is comparable to the < 4
2% of all particles as aggregates in control PRP previ-
ously reported for 34 healthy donors (14). Samples of
PRP 1:10 activated with ADP or PMA, as described
above, contained <5% of all particles as doublets, and
< 1% as triplets, i.e., > 95% singlets, for r ranging from
3 s to 15 min for ADP, and from 10 to 25 min for PMA.
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Given an uncertainty in aggregation of platelet samples
of < 5%, we have compared mean Fl values for the total
platelet population versus 95% of the population with
the top 5% gated out for largest FSC values: we found
<8% reduction in Fl values for vT and Flmax for either
ADP or PMA as activators. This is clearly an overesti-
mate, as mean FSC did not in fact significantly increase
for PRP samples stirred for 3 s with 10 p,M ADP to yield
20% of particles as doublets and triplets. Moreover, any
effects due to aggregation are further reduced as ratios
of mean Fl are used to obtain k1 and k2 values.
Time course of FITC-PAC1 binding to
platelets by dilution quenching
For a given condition of preactivation (' values) and
incubation with FITC-PAC1 (t values), fluorescence
histograms were obtained at selected t values by rapid
dilution quenching and measurement of >2,500 cells.
This is demonstrated in Fig. 4 using PRP incubated
together with 100 ,uM ADP (T = 0) and FITC-PAC1 (at
saturating concentrations) for t values ranging from 15 s
out to 45 min of PAC1 incubation, and contrasted to
unactivated PRP in the absence of PAC1 (t = 0). Fluo-
rescence histograms were also obtained in parallel for
unactivated PRP incubated with FITC-PAC1. Plots of
Fl versus PAC1 incubation times were thus determined
from such histograms, and the time course for specific Fl
(corrected for nonspecific binding) was obtained as
shown in Fig. 5 for platelets maximally preactivated with
PMA. The slope of the initial linear rise in specific Fl
yields v, whereas the maximal rise in specific Fl yields
Fl.. (see Eq. 9).
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FIGURE 4 Dynamics of fluorescence histograms in activated platelets
with time-dependent binding of FITC-PACL. A fluorescence histo-
gram is shown for unactivated PRP without FITC-PACI (t = 0).
Parallel PRP samples were then incubated with 100 ,uM ADP and
FITC-PAC1, the suspension was dilution quenched after 15 and 30 s
out to 45 min, and fluorescence histograms obtained at each of these
times.
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FIGURE 5 Time course of mean fluorescence associated with resting
and activated platelets using FITC-PAC1, EDTA and a nonspecific
IgM probe. The mean fluorescence values (Fl) were obtained for
unactivated PRP (0) and for PRP maximally preactivated with 0.2 ,uM
PMA ( = 25 min) (U) as a function of incubation time with
FITC-PAC1; these were determined from histograms as shown in Fig.
3. The Fl versus t curve for PMA activated platelets (-) was then
corrected for nonspecific binding by curve subtraction (--). The
initial rate of increase in Fl (v) and maximal extent, Fl.., are
indicated. The uncorrected Fl curves are also shown for (a) the above
with 5 mM EDTA (0) added 1 min before PMA addition(s), and (b) a
nonspecific IgM (Bll ) for control (A) and PMA activated (A) as for
PACL. One curve (--- ) is generated to represented these four
controls, PRP ± EDTA and PRP ± PMA + Bll1. Identical results
were obtained with BI10 and 9604 IgM's (see Methods).
Specificity of FITC-PAC1 binding to
its fibrinogen receptor
To explore the possibility that the rapid binding of
FITC-PAC1 to activated platelets (Figs. 5 and 6) arises
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FIGURE 6 Comparison of overall kinetics of PAC1 binding to plate-
lets activated with ADP and PMA. Corrected Fl values were obtained
for platelets maximally preactivated with 0.2 F.M PMA (r = 25 min;
[-]) and 100 ,uM ADP (T = 0-10 s; [0]) as a function of FITC-PACI
incubation time (t) for five donors for t values ranging from 15 s out to
10 min. The time course for PMA added with PAC1 (v = 0 min; [O]) is
shown for one donor. Fl values are normalized by comparing to Fl.
values measured for t = 45 min, separately done for each donor and for
each activator. All donors were common for both activators.
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from a rapid entry into membrane compartments open-
ing with platelet activation, quite apart from specific
binding to the fibrinogen receptor GPIIb-IIIa, we com-
pared the binding kinetics of FITC-labeled IgM antibod-
ies which bind nonspecifically to the platelet surface
and/or to phospholipids. All three such antibodies
(Bil0, Bill, 9604) (17) showed rapid Fl saturation
curves, independent of platelet activation, as shown for
one of these in Fig. 5. In addition, we found that
activation of platelets in the presence of 5 mM EDTA,
which allows full shape change (21) but inhibits binding
of both Fb and of PAC1 to the specific GPIIb-IIIa
receptor for Fb (5, 6), showed a rapid binding as seen for
all other "nonspecific" binding (Fig. 5). The nonspecific
binding is consistent with a dynamic equilibrium be-
tween adsorption and desorption of the antibodies with
an average "residence" time of the order of 10 s.
Comparison between experimental
results and theory
Condition I
When both activator and probe are added together
(T = t = 0), Eq. 4 predicts an S-shaped curve for Fl
versus time for PAC1 binding to platelets, as seen in
Fig. 6 for PMA at T = 0. Using Eq. 2b, we calculate k, for
platelets activated with PMA ( =0) from the initial
slope of Fl/Flu. (V = nnlmax), shown in Fig. 6 to be 10-2
min-'. Using Eq. 10, we calculate k2m. for maximally
preactivated platelets from the initial slope (V) = 0.4
min-'. With these values of k1 and k2, Eq. 4 predicts
reasonably the low Fl/Flma, values at low t values (<5
min) for PMA added at T = 0 in Fig. 6. As Eq. 4 is only
valid for short times, it is not surprising that this
equation greatly overestimates values at larger t (> 15
min).
Quite surprisingly, no S-shape curve was seen when
100 ,uM ADP was added together with FITC-PAC1
(compare Figs. 6 and 7 for T = 0 and Fig. 8 B). A
comparison of early time points for binding of FITC-
PAC1 added to platelets together with ADP (T = 0)
shows rapid and significant binding by 5 s, with back-
extrapolation to a zero intercept in all four donors
examined (Fig. 7). These results suggest that whereas
initial FbR expression with PMA activation is slow (see
also Fig. 9), ADP activation expresses FbR on the
platelet surface in << 5 s of activation; this corresponds
to ki >» l/ s-1 or > 12 min-'.
Rate of expression of FbR (k1)
Condition 2A
The time courses for PAC1 binding to platelets with
varying preactivation times (T) are shown for platelets
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FIGURE 7 Initial rate of Fl increase for ADP added together with
FITC-PAC1 (r = 0). PRP (1:10) was incubated with 100 p.M ADP and
FITC-PAC1 added at the same time (r = 0) and suspensions were
dilution quenched at t = 5 and 10 s, out to 60 s, with Fl values obtained
at each time point, as shown for four different donors. Fl values have
been corrected for nonspecific binding and normalized to Fl,,,,, (t = 45
min) values determined for each donor; these were 164 (V), 175 (A),
350 (A), and 500 (U) fluorescence units. Regression lines have been
drawn from 0 Fl to the two earliest t points measured in each case to
illustrate the range of initial PAC1 binding rates.
activated with PMA (Fig. 8A) and ADP (Fig. 8 B). By
plotting the initial rate of increase in specific Fl due to
PAC1 binding determined from these curves (v) as a
function of T, we can determine the rate of expression
(kI) of PACi binding sites (FbR) from the initial slope as
predicted by Eq. 9a, and shown in Fig. 9. In the case of
PMA activation, there appears to be a slow initial
expression of FbR over the first 10 min of activation
(k, 0.01 min-'; Table 1). However, for ADP activa-
tion, essentially the same initial rate of increase in Fl (v)
was seen whether FITC-PAC1 was added with ADP
(7 = 0) or added 1, 2, or 3 s later (data shown for one of
three donors so evaluated for T = 0 and 3 s in Fig. 8 B).
This is consistent with maximal FbR expression occur-
ring well within 3 s and a k, value > 20 min-' (Table 1).
Rate of PACI binding (k2 mi) for
maximally preactivated platelets
Condition 2B
Eq. 9 predicts that for a fixed concentration of FITC-
PAC1, k2mn will be constant independently of varying
FlI,,. values for qualitatively identical PAC1 binding
sites: i.e., vmax/Flmax = k2nm constant. We chose
platelets maximally preactivated with 0.2 ,M PMA for
T = 25-30 min to test Eq. 10 because neither vm.. nor
Flmax changed beyond T = 25 min, tested out to 85 min.
We first compared vm./Flm. values within a given PRP
for distinct platelet subpopulations electronically gated
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FIGURE 9 Initial rate of PAC1 binding (v,) as a function of platelet
T _ preactivation time (T) for ADP and PMA. The initial rate of Fl
0,3 secs. increase (v,) was determined from the initial slopes of the curves
10,30,60secs. shown in Fig. 8A and B as a function of preactivation time (r),
5'115 mins. respectively for PMA (0) and ADP (0) activation. The vT values are
normalized to maximal values (vm,) obtained for Xr> 25 min and 0-3 s,
respectively for PMA and ADP activation (data in Fig. 8). Note that
v/lvm, = 1.0 for ADP at the earliest time point measured ('T = 0, t = 5
, s), so that k, cannot be determined from the initial slope of v,vml, for
40 50 60 ADP, as it can for PMA, using Eq. 9. Note that for constant k2, vJ
TIME Cs) v.. = n,ln,.. (cf. Eq. 8).
FIGURE 8 Dependence of initial rate of PAC1 binding to activated
platelets on preactivation time. Corrected Fl values versus incubation
time with FITC-PAC are shown for one typical donor for PRP
activated at different times T with (A) 0.2 ,uM PMA, and (B) 100 F.M
ADP. For ADP, Fl was averaged for T = 5 or 15 min, as they were
identical.
from the 20% of the largest forward scatterers (L) and
the 20% of the smallest forward scatterers (S). These L
and S platelets had distinct Vm. and Flm. values, but as
predicted by Eq. 10, VJVS equals FlJFl. for each of the
five donors evaluated for varying Flm. values (Table 2).
The ratios in the last column of Table 2 effectively
represent k2(S):k2(L) values, which are constant.
We next compared vmax and Flmax values for different
donors for both ADP and PMA maximally preactivated
PRP samples (Table 3). The mean k29n values for ADP
and PMA, derived from vmaIFlmax values for m. = 24
,ug/ml PAC1, are respectively shown in Table 3. Values
of k2m. were within 1 SD from the mean for 6 of 11
donors and 6 of 9 donors for PMA and ADP-activated
platelets, respectively; the balance of donors had k2m.
values within 1.2 SD of the mean. For the former
"normal" donors, vma varied linearly with Flm.., with r
values for a linear regression of 0.83 and 0.74, respec-
tively, for PMA and ADP-activated platelets (figure not
shown). A compariso'n of parameters for the same PRP
preparation, done for six donors (Table 3), shows that
PMA-activated platelets maximally express 1.8 x
more PAC1 binding sites (FbR) than do the ADP-
activated platelets.
We can calculate the efficiency of PAC1 binding to its
specific receptor sites using Eq. 12. For PMA activation
k,m0 = 0.40 min-t, m0 = 24 g/m3, and PAC1 mol wt = 106
dalton; thus, k2 = 4 x 10-22 m3s-1. Taking the maximal
number of PAC1 sites, S, to be -2 x 104 per PMA-
activated platelet (4-6). It follows from Eq. 12 that the
efficiency of binding a( 0.16 or 15%. Because
S(PMA)/S(ADP) = Flm.(PMA)/Flm.(ADP) 1.8, we
TABLE i Rate constants for the expression and occupation of
PAC1 binding sites on human platelets*
Rate of Rate of Efficiency of
Activator expression occupancy occupancy
type concentration k,t k2t al
P.M min-' x 107M-'min-I %
PMA 0.2 (a) 0.01
(b) 0.20 1.7 13
ADP 100 > 20 0.8 4
*Data is derived from Fig. 9, Table 3, and Theory; tkl and k2 are the
forward rate constants, respectively, for the expression of PAC1
binding sites and the binding of PAC1 to these maximally expressed
sites; mo = 24 pg/ml and PAC1 mol wt = 106 dalton; '(a) and (b) refer
respectively to the initial slow phase and subsequent rapid phase of
PAC1 site (FbR) expression after PMA activation, whereas k, for ADP
activation is a minimal value due to the full expression of FbR within
<3 s; la is the efficiency of binding of PAC1 to maximally activated
platelets (Eq. 12), where S,,., has been reported to be - 20 x 103 FbR
sites per platelet for PMA activation. (10).
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TABLE 2 Summary of relationship between maximal rate of
binding (v,,,) and maximal extent of binding (Fl,,) for PMA
(0.2 plM)-activated platelets for Intradonor analysis
F1.* V nat
LI s L:S L S L:S F1L/FI:VL/VS
FU FU/s
785 226 3.5 4.0 1.1 3.6 0.97
1000 195 5.1 5.9 1.3 4.5 1.13
508 152 3.3 5.8 2.2 2.6 1.27
654 201 3.3 8.0 3.1 2.6 1.27
450 110 4.1 5.3 1.6 3.3 1.24
1.18 ± 0.101
*Fl, was measured for PMA preactivation T = 25 min, PAC1
incubation time (t) of 30 min expressed in fluorescence units (FU);
FITC-PAC1 final concentrations (mi) were 26 + 3 and 40 p.g/ml,
respectively, for donors one to four and donor five; tv. corresponding
to the initial rate of binding (typically measured at t = 10-20 s); L and
S are platelet subpopulations corresponding to, respectively, the upper
and lower 20% of cells on the forward scatter histogram; 'Mean
value ± SD for this column; the ratios shown correspond to relative k2
values for S:L subpopulations (see Eq. 10).
calculate an a value for ADP-activated platelets of - 5%
(Table 1).
Dependence of rate constants on
type or duration (T) of activation
Condition 3
The rate of expression of PAC1 binding sites (kj) is
-20-fold greater after 20 min of PMA-activation of
TABLE 3 Comparison of Initial rate (v,,,,) and maximal extent
(Fl,,, of PACI binding for platelets maximally preactivated
with ADP (100 MM) or PMA (0.2 MM) for different donors
Number
Activator T of donors vma* Fl,,* k2mo
FU/s FU min-'
ADP 1-10 s 9 1.1 ± 0.4* 274 ± 65 0.24 ± 0.07
PMA 25 min 11 3.4 1.1' 451 80 0.45 0.12
Parameter analysis1 6 common 3.0 ± 0.6 1.8 ± 0.6 1.7 ± 0.3
PMA:ADP (2.4-4.0) (1.3-2.7) (1.2-2.1)
*Calculated from individual donors then pooled to obtain average ± 1
SD: *Seven/nine donors determined with FITC-PAC1 preparation one
(MO = 24 Fg/ml final; for two donors with preparation two (40 Ag/ml)
we multiplied v,,P x 0.6 (see Eq. 10); '6/11 donors with preparation
one, and five with preparation two (mo set as in above); 'Six donors
where both activators were evaluated in parallel were chosen to
calculate individual ratios for v,,.,,, Fl,,, and vIFl,,.F. (= k2min) for
PMA versus ADP activation e.g., Vm.,, (PMA): v. (ADP); the
average ± SD for these pooled values are reported, with the range
shown in brackets; differences between PMA and ADP values were
significant with p < 0.01, evaluated with a one-tailed paired t-test;
'MO = 24 ,ug/ml (see *, §). Identical k2mo values and SD were obtained
for six common donors, as shown for the 9 and 11 donors.
platelets (kI - 0.2 min-') than in the initial phase of
platelet activation (values are shown in Table 1, using
data in Fig. 9 and Eq. 2c). Activation with ADP causes
PACl-binding sites to be maximally expressed in < 3 s
with a k1 > 20 min-', i.e., > 1,000 times faster than the
maximal k, seen with PMA activation (Table 1).
The rate of binding of PAC1 molecules (k2) to
PACl-binding sites expressed on activated platelet sur-
faces was found to be maximal within <«5 s of ADP
activation, but appeared to "decay" with increasing
preincubation times (Figs. 8 and 9); however, Flm.
values were unchanged ( <5% differences in values for
T= 0, 10 s, 60 s, and 15 min for four experiments). This
is consistent with negligible loss of expressed PAC1 sites
(kl, - 0). It thus appears that k2 (T) decays by -33%
and 66% within - 1 and 5 min of maximal activation of
platelets by ADP (Fig. 8 and 9). This corresponds to the
equivalent decay in Vm,, and actual efficiency of binding
(a) with increasing T (Eq. 14).
Maximal k2 and a values have also been found to
depend on the activator chosen. Thus, the k2 values for
binding of PAC1 to platelets maximally preactivated
with PMA versus ADP are - 1.7 (Tables 1 and 3). As
discussed for Eq. 11 in Theory, this represents decreas-
ing accessibility of the PAC1 binding sites to the PAC1
probe. In addition, the relative efficiencies of PAC1
binding to maximally activated platelets, a (PMA)/a
(ADP) - 3.1, i.e., the efficiency of PAC1 binding to
PMA-activated platelets is - three times greater than
for ADP-activated platelet surfaces. This is directly
reflected in vm values for PMA versus ADP (Table 3),
as predicted by Eq. 14.
DISCUSSION
The mammalian platelet is a particularly useful model
for the studies of activation and time-dependent expres-
sion of new receptors on the plasma membrane. Previ-
ous studies of PAC1 binding to activated platelets
(5, 6, 10), as well as of other monoclonal antibodies
specific for platelet membrane glycoproteins such as
GPIIbdIIIa (8, 12, 16, 22), GPIIb (22), GPIb (16), and
a-granule GMP-140 (6), have generally evaluated maxi-
mal binding of the probe to platelet surfaces, obtained
from equilibrium binding at saturating conditions for the
antibody probe used. These studies are most widely
conducted with "2I-labeled antibodies (5, 8, 10, 12, 16, 22)
and encounter the possible problems associated with
platelet pelleting to remove the unbound probe. We
have demonstrated, by both theoretical and experimen-
tal considerations, that the very rapid expression of new
receptors on the platelet surface can be measured
dynamically within seconds of activator addition by flow
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cytometry using saturating concentrations of a probe
binding to these receptors.
We have found that the monoclonal antibody PAC1, a
specific probe for transformed GPIIb-IIIa serving as a
FbR, binds to both control and activated platelets with
overall kinetic curves described approximately by Fl =
Flmax (1 e -t/tads), where t adsorption - 0.3 and 17 min,
respectively, corresponding to a "lie" time for adsorp-
tion. Deviations in Fl values with increasing PAC1
binding times (t) will occur, as in Fig. 6, due to changes
in k values with activation time T or heterogeneity in
PAC1 binding sites on the activated platelet surface.
We have confirmed the theoretical prediction (Eq. 10)
that on-rate of FITC-PAC1 (v,) will reflect the number
of PAC1 binding sites (FbR sites) present at the time of
addition of the FITC-PAC1 to platelets preactivated for
a given time T. This was best shown using platelets
maximally preactivated with PMA, where both v. and
Flmax, corresponding to the maximal on-rate and number
of FbR sites expressed, respectively, remain constant
with time beyond T = 25 min. These intradonor compar-
isons of platelets with different light scatter properties
and different vmax and Flmax values supported this hypoth-
esis (Table 2).
We observed that Flmax for PMA activated platelets
was two times greater than for ADP activated platelets
(Table 3). This suggests that twice as many GPIIb-IIIa
transformed receptors are expressed on the platelet
surface with PMA than with ADP, as reported from
studies with 1"I-PAC1 (10). This could arise from a
greater efficiency of conversion from the same pool of
"resting" GPIIb-IIIa and/or recruitment of a new pool of
receptors available from the surface connecting system
(SCCS) (23) or from a-granules (11). These mechanisms
will be unravelled through the use of appropriate anti-
bodies measuring total GPIIb-IIIa (8, 16, 22) and extent
of a-granule release (16).
Only one study to date has examined rates of antibody
binding to platelets as a function of platelet activation, in
addition to measurements of maximal equilibrium bind-
ing. This was done using "2I-labeled monoclonal antibod-
ies to GPIIb-IIIa (8), but preactivation times (T) were
only 30 s with 100 p,M ADP, and the earliest PAC1
binding time point (t) was 1-2 min for studies with
washed platelets and PRP. This approach did demon-
strate that the on-rate for the IgG binding measured at
1-2 min was increased for one of two antibodies tested
when platelets were preactivated with ADP, although
the maximal number of IgG binding sites (GPIIb-IIIa)
did not significantly change with activation. Based on
our observations with FITC-PAC1, these on-rates may
be larger and even more distinct for smaller preactiva-
tion times T, as well as for earlier IgG reaction times
(t - 15-30 s) (see Figs. 3, 5, 6, and 8). In addition, the
PAC1 probe is more direct as it does not bind to
"resting" platelets (5, 6, 10).
We have also found, as reported by Coller (8), that
off-rates for IgM (PAC1 and others) and IgG evaluated
to date (all with Kd values between 0.1 and 1 nM), are all
extremely slow, so that dilution quenching is an effective
way to arrest probe binding to the activated platelets. In
effect, on-rates at times < 5 s of probe addition can be
readily determined. The initial rates of Fl increase we
have measured, v, are effectively such on-rates for
FITC-PAC1 binding to FbR. Studies of v with new
probes or molecules like Fb should however be preceded
by such measurements of off-rates. Moreover, reversibil-
ity of binding and/or reversibility of expression of the
FbR can be monitored directly by measuring off-rates in
real time (see Fig. 3 B).
Our results for initial on-rates for PAC1 to activated
platelets, as a function of preactivation times T, Vt,
demonstrate the new type of information available with
this approach. This allows determinations of rates of
expression of PAC1 or Fb binding sites (FbR) (kI)
(Fig. 9, Table 2). The results suggest that PAC1 binding
sites, and therefore FbR sites, are all maximally trans-
formed from a pool of GPIIb-IIIa within - 1 s of
activation. This would correspond to -10,000 new
PAC1 binding sites generated with maximal ADP activa-
tion (10), within - 1 s. This suggests that the expression
of FbR will not be rate-limiting in platelet aggregation,
which has an onset of 1 s and a t1,2 of 3-4 s, for in vitro
assays made with PRP (14, 15). Further studies along
this line will more firmly establish this point. Equally
surprising were the observations that k2 values "decayed"
with longer preincubation times T (1-15 min), though
Fl., values were unchanged. This is consistent with a
change in the organization of the FbR receptor and/or in
its microenvironment with time, with conservation of
total surface FbR numbers. These results demonstrate
that platelets do not become refractory with respect to
total number of FbR, but rather reorganize their surface
which can alter "steric accessibility" of the FbR sites.
The relationship to lack of refractoriness in early micro-
aggregation but complete refractoriness to advanced
macroaggregation occurring with ADP (15) remains to
be determined.
The measurements of k, for PMA-activated platelets
(Fig. 9, Table 2) suggest that < 1% of maximally
expressed FbR are needed to support aggregation in-
duced by PMA with extremely low rates of FbR expres-
sion (compare k, values in Table 2), as turbidimetrically
measured aggregation is complete within 4 min of 0.2
,M PMA-activation. Other explanations, including the
role of other receptors, must also be considered in light
of these observations.
Comparisons of the initial on-rate of PAC1 (vm..) for
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platelets maximally preactivated with PMA (r > 25
min) versus ADP (T = 0-10 s) show that PAC1 binds
about three times as fast onto fibrinogen binding sites
(FbR) generated by PMA than for sites induced byADP
(Tables 1 and 3); this corresponds to PAC1 binding
three times more efficiently to platelet surfaces maxi-
mally activated with PMA than to the same platelets
activated with ADP (compare a in Table 1). The rate
constants for PAC1 binding to these maximally activated
platelets (k2), obtained from vmu/Flm. values, are two
times greater for PMA than for ADP-activated platelets
(Tables 1 and 3). These larger values reflect the greatly
enhanced specific receptor accessibility to PAC1 mole-
cules on PMA-activated surfaces compared to ADP-
activated surfaces, suggesting distinct types or organiza-
tion of FbR sites associated with different agonists.
The observation that Flma was unchanged for ADP
preactivation times T < 15 min also suggests that Fb
does not become "irreversibly" bound to platelets acti-
vated in PRP at room temperature with 100 pmADP for
as long as 15 min (T value) before addition of PACL.
Thus, parallel studies with more direct measurements of
Fb binding (24) are needed to demonstrate the possibil-
ity that bound Fb which can no longer be dissociated
with EDTA (25) is still readily displaced by PACL. The
decay in k2 (T) with constant Flm. seen with ADP (Fig. 9)
may be related to the altered organization of bound Fb
with activation time (26).
The most likely explanations for the observed differ-
ences in k1 and k2 occurring with activator type and
postactivation time (Tables 1 and 3) lie in (a) the known
ability of the transformed GPIIb-IIIa (FbR) to cluster
after platelet activation (4, 13, 26) and/or in response to
multivalent ligands (27, 28); and (b) the presence of
"internal" pools of GPIIb-IIIa from sources such as the
a-granule (2, 4, 11, 13, 23). For example, clustering of
transformed GPIIb-IIIa (FbR) could readily slow down
PAC1 binding due to lowered numbers of receptors per
unit area of surface and/or due to steric hindrance
(reduced v, k2, and a), whereas leaving equilibrium
maximal binding intact (normal Flmu). Parallel studies
using flow cytometry and electron microscopy, which will
help resolve these questions, are in progress.
Our kinetic approach using flow cytometry is ideally
suited for assessing the dynamics of FbR expression
from VT and Fl.,, values for size-dependent platelet
subpopulations by electronic gating, obviating the need
for physical separation of the platelets (29). This ap-
proach is presented in Part II (30).
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